Last reviewed · How we verify
NCT06908070: CROWD
Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab
Phase 4 trial testing Consolidation durvalumab in Non-small Cell Lung Cancer Stage III in 38 participants. Currently enrolling.
17 December 2026
Quick facts
| Lead sponsor | Idris Bahce |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 38 |
| Start date | 17 December 2024 |
| Primary completion | 17 December 2026 |
| Estimated completion | 17 December 2028 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Consolidation durvalumab — full drug profile →
Conditions studied
- Non-small Cell Lung Cancer Stage III — all drugs for Non-small Cell Lung Cancer Stage III →
Sponsor
Idris Bahce
Who can join
18 and older, any sex, with Non-small Cell Lung Cancer Stage III. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Lung cancer presents a significant treatment challenge, particularly in the heterogeneous stage III NSCLC patient population. While chemotherapy combined with high-dose radiotherapy (60 Gy in 30 fractions of 2 Gy once daily) is currently the recommended approach for unresectable stage III cases, it is associated with significant rates of locoregional and distant failures. Notably, the introduction of durvalumab consolidation therapy after chemoradiotherapy (CRT), as demonstrated in the PACIFIC study, has shown improved overall survival, primarily attributed to enhanced distant control. This improvement prompts further interest in investigating whether further improvements in locoregional control can lead to improved survival for patients. The present study aims to evaluate the feasibility of post-CRT surgery in patients with initially considered unresectable stage III (non-N3) NSCLC.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06908070
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Consolidation durvalumab
Trials testing the same drug.
- NCT04364048 — Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer · Phase 2 · terminated
Other recruiting trials for Non-small Cell Lung Cancer Stage III
Currently open trials in the same condition.
- NCT06634199 — Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients · recruiting
- NCT05557552 — Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer · NA · recruiting
- NCT04728724 — Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer · Phase 2 · recruiting
- NCT05398094 — Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy · Phase 2 · recruiting
- NCT04685070 — Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lun · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06908070 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Idris Bahce
- Last refreshed: 3 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06908070.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing